Top ▲


Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 2852

Nomenclature: CD79B

Family: CD molecules

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 229 17q23.3 CD79B CD79b molecule
Mouse 1 228 11 68.89 cM Cd79b CD79B antigen
Rat 1 228 10q32.1 Cd79b CD79b molecule
Gene and Protein Information Comments
The table lists the longest isoform of human CD79B, shorter isoforms are reported.
Previous and Unofficial Names Click here for help
immunoglobulin-associated beta | IGB | CD79b molecule, immunoglobulin-associated beta | Cd79b molecule, immunoglobulin-associated beta
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file go icon to follow link

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
polatuzumab vedotin Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding - - 1
Antibody Comments
The ADC iladatuzumab vedotin (DCDS0780A) is being developed by Hoffmann-La Roche for potential treatment of B-cell non-Hodgkin's lymphoma. It is being evaluated in Phase 1 clinical trial NCT02453087.
Immunopharmacology Comments
CD79B is a component of the multimeric B cell antigen receptor (along with CD79A and a membrane-bound antibody that acts as the antigen recognition moiety). The CD79A/B component is responsible for signal transduction. The B cell antigen receptor complex is reported to be involved in the pathogenesis of various B cell-derived lymphoid cancers [2-3]. Inhibitors of components of B cell receptor signalling are being pursued as novel therapeutics for lymphoid neoplasms, e.g.polatuzumab vedotin is an investigational antibody-drug conjugate targeting a toxic payload to CD79B +ve cells in various hematological malignancies.
Cell Type Associations
Immuno Cell Type:  B cells
Immuno Process Associations
Immuno Process:  B cell (activation)
Immuno Process:  Immune regulation
Immuno Process:  Immune system development
Immuno Process:  Cellular signalling
Immuno Process:  T cell (activation)
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Agammaglobulinemia 6, Autosomal recessive; AGM6
Synonyms: Agammaglobulinemia [Disease Ontology: DOID:2583]
Autosomal agammaglobulinemia [Orphanet: ORPHA33110]
Disease Ontology: DOID:2583
OMIM: 612692
Orphanet: ORPHA33110
General Comments
This protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590.


Show »

1. Chen Y, Dennis M, Dornan D, Elkins K, Junutula JR, Polson A, Zheng B. (2012) Anti-CD79B antibodies and immunoconjugates and methods of use. Patent number: US8088378 B2. Assignee: Genetech Inc.. Priority date: 16/07/2007. Publication date: 03/01/2012.

2. Mraz M, Kipps TJ. (2013) MicroRNAs and B cell receptor signaling in chronic lymphocytic leukemia. Leuk Lymphoma, 54 (8): 1836-9. [PMID:23597135]

3. Seda V, Mraz M. (2015) B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol, 94 (3): 193-205. [PMID:25080849]

How to cite this page

CD molecules: CD79B. Last modified on 07/08/2019. Accessed on 24/06/2024. IUPHAR/BPS Guide to PHARMACOLOGY,